Cargando…

Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)

OBJECTIVE: To examine the efficacy and safety of lixisenatide (20 μg once daily, administered before the morning or evening meal) as add-on therapy in patients with type 2 diabetes insufficiently controlled with metformin alone. RESEARCH DESIGN AND METHODS: This was a 24-week, randomized, double-bli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahrén, Bo, Leguizamo Dimas, Aniceto, Miossec, Patrick, Saubadu, Stéphane, Aronson, Ronnie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747937/ https://www.ncbi.nlm.nih.gov/pubmed/23536584 http://dx.doi.org/10.2337/dc12-2006

Ejemplares similares

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
por: Riddle, Matthew C., et al.
Publicado: (2013)

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
por: Riddle, Matthew C., et al.
Publicado: (2013)

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
por: Rosenstock, Julio, et al.
Publicado: (2013)

Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S
por: Onishi, Yukiko, et al.
Publicado: (2015)

Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials
por: Blonde, Lawrence, et al.
Publicado: (2016)

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
por: Fonseca, Vivian A., et al.
Publicado: (2012)

Efficacy and safety of lixisenatide as add‐on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal‐O Study
por: Dailey, George E., et al.
Publicado: (2019)

Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal‐L‐C randomized trial
por: Yang, Wenying, et al.
Publicado: (2017)

Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials
por: Eto, Kazuhiro, et al.
Publicado: (2015)

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)*
por: Seino, Y, et al.
Publicado: (2012)

Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies
por: Feng, Wenhuan, et al.
Publicado: (2021)

Morning and evening exercise
por: Seo, Dae Yun, et al.
Publicado: (2013)

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
por: Kapitza, C, et al.
Publicado: (2013)

Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035
por: Rosenstock, Julio, et al.
Publicado: (2017)

Insulin glargine/lixisenatide fixed‐ratio combination improves glycaemic variability and control without increasing hypoglycaemia
por: Aronson, Ronnie, et al.
Publicado: (2018)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen, Andreas B, et al.
Publicado: (2013)

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
por: Ratner, R E, et al.
Publicado: (2010)

On the Comparative Frequency of the Morning and Evening Pulse
por: Stratton, Thomas
Publicado: (1843)

Getting even /
por: Allen, Woody, 1935-
Publicado: (1978)

Morning/Evening Differences in Somatosensory Inputs for Postural Control
por: Bougard, Clément, et al.
Publicado: (2014)

The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
por: Bain, Stephen C.
Publicado: (2014)

Time of administration important? Morning versus evening dosing of valsartan
por: Zappe, Dion H., et al.
Publicado: (2015)

Evaluation of evening versus morning levothyroxine intake in elderly (MONIALE)
por: Giassi, Karina, et al.
Publicado: (2019)

Sex and limb comparisons of neuromuscular function in the morning versus the evening
por: Augsburger, Garrett R., et al.
Publicado: (2022)

Time-of-day effects on eyewitness reports in morning and evening types
por: Yaremenko, Sergii, et al.
Publicado: (2022)

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus()
por: Van Gaal, Luc, et al.
Publicado: (2014)

Evaluation of adherence to morning versus evening glaucoma medication dosing regimens
por: Kahook, Malik Y, et al.
Publicado: (2007)

Beyond the Low Frequency Fluctuations: Morning and Evening Differences in Human Brain
por: Fafrowicz, Magdalena, et al.
Publicado: (2019)

Casein Protein Supplementation in Trained Men and Women: Morning versus Evening
por: ANTONIO, JOSE, et al.
Publicado: (2017)

Neuro-Cognitive Profile of Morning and Evening Chronotypes at Different Times of Day
por: Venkat, Nanditha, et al.
Publicado: (2021)

Morning versus Evening Intake of Creatine in Elite Female Handball Players
por: Jurado-Castro, Jose Manuel, et al.
Publicado: (2021)

Effect of Morning and Evening Exercise on Energy Balance: A Pilot Study
por: Creasy, Seth A., et al.
Publicado: (2022)

Can Levothyroxine Be Taken as Evening Dose? Comparative Evaluation of Morning versus Evening Dose of Levothyroxine in Treatment of Hypothyroidism
por: Rajput, Rajesh, et al.
Publicado: (2011)

Evenness indices once again: critical analysis of properties
por: Kvålseth, Tarald O
Publicado: (2015)

Evening and morning alterations in Obstructive Sleep Apnea red blood cell proteome
por: Feliciano, Amélia, et al.
Publicado: (2017)

Time and age trends in morning and evening protein intakes of German children and adolescents
por: Roßbach, Sarah, et al.
Publicado: (2018)

Morning and evening behavior in children and adolescents treated with atomoxetine once daily for Attention-Deficit/Hyperactivity Disorder (ADHD): Findings from two 24-week, open-label studies
por: Wehmeier, Peter M, et al.
Publicado: (2009)

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial
por: Watada, Hirotaka, et al.
Publicado: (2020)

Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study
por: Rorie, David A, et al.
Publicado: (2016)

Lixisenatide as add-on therapy to basal insulin
por: Brown, Dominique Xavier, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ojbctj1bkj7rt91idlb9tc385p